Business Context and Reporting Period
This Form 8-K, dated March 1, 2022, reports the completion of the separation of Zimmer Biomet Holdings, Inc.'s spine and dental businesses into a new independent public company, ZimVie Inc. (trading symbol "ZIMV"). The separation was effected via a distribution of 80.3% of ZimVie's outstanding common stock to Zimmer Biomet stockholders of record as of February 15, 2022.
Key Financial Metrics and Capital Structure
This filing is a current report regarding a corporate transaction and does not contain audited financial statements, revenue, profit, or cash flow data for the reporting period.
- Ownership Retention: Zimmer Biomet retained 19.7% of the outstanding shares of ZimVie common stock following the distribution.
- Distribution Ratio: One share of ZimVie common stock was distributed for every ten shares of Zimmer Biomet common stock owned.
- Debt Facilities: The company holds a Five-Year Revolving Credit Agreement and a 364-Day Revolving Credit Agreement, both dated August 20, 2021, with JPMorgan Chase Bank, N.A. as administrative agent.
Material Changes Versus Prior Period
The primary material change is the structural separation of the spine and dental segments, which are now operated by ZimVie. Zimmer Biomet has entered into definitive agreements to govern the post-separation relationship, including:
- Asset and Liability Allocation: Cross-indemnities place financial responsibility for ZimVie business obligations with ZimVie and remaining business obligations with Zimmer Biomet.
- Transition Services: Both entities will provide interim services (IT, HR, finance, etc.) to one another, generally terminating no later than March 31, 2025.
- Manufacturing: Transition manufacturing and supply agreements are in place, generally terminating no later than March 1, 2027.
- Intellectual Property: Perpetual, royalty-free licenses have been granted to both parties for specific IP rights retained by the other.
Guidance, Outlook, Risks, and Unusual Items
This filing does not provide forward-looking financial guidance or management commentary on future earnings. Key risks and contingencies identified include:
- Tax Contingencies: A Tax Matters Agreement governs liabilities if the distribution fails to qualify as tax-free. ZimVie is generally responsible for taxes resulting from its own actions or breaches, while Zimmer Biomet is responsible for taxes arising from its own actions.
- Debt Waivers: Waivers were obtained on February 25, 2022, to permit ZimVie to incur debt and grant liens immediately prior to the separation without triggering a default under Zimmer Biomet's credit agreements.
- Regulatory Approvals: Certain activities related to ZimVie businesses may continue to be operated by Zimmer Biomet in specific jurisdictions until requisite governmental approvals are received.
Investor Verification Checklist
- Verify the trading status and initial market capitalization of ZimVie Inc. (ZIMV) on the Nasdaq Stock Market.
- Review the full text of the Separation and Distribution Agreement (Exhibit 2.1) for specific asset transfers and indemnification caps.
- Confirm the terms of the retained 19.7% stake in ZimVie and the associated voting proxy arrangements.
- Assess the duration and cost implications of the Transition Services Agreement and Manufacturing Supply Agreements.
- Monitor the status of governmental approvals required to finalize the transfer of activities in specific jurisdictions.